On March 17, 2016 Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, reported that data from five accepted abstracts of tazemetostat (EPZ-6438), its clinical stage inhibitor of EZH2, will be presented during the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2016 being held April 16-20 in New Orleans (Press release, Epizyme, MAR 17, 2016, View Source [SID:1234509613]). Schedule your 30 min Free 1stOncology Demo! Tazemetostat is a first-in-class EZH2 inhibitor currently in phase 2 studies in advanced B-cell non-Hodgkin lymphoma (NHL) and certain genetically defined solid tumors. Among the data to be presented at the meeting are studies on the food effect and drug interaction characteristics of tazemetostat.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased to be able to present these important new data, including mechanism of action and biomarker studies that continue to guide us in developing patient selection criteria for tazemetostat," said Peter Ho, M.D., Ph.D., Chief Medical Officer, Epizyme. "Additionally, the clinical pharmacology studies being presented have helped to more fully inform the dosing of patients in our ongoing clinical programs."
Planned Presentations:
Evidence of EZH2 Dependent and Independent Mechanisms of Tazemetostat Treatment Emergent Resistance in Models of Diffuse Large B Cell Lymphoma
Speaker: Carly T. Campbell, Epizyme, Inc.
Session Title: Mechanisms of Drug Resistance 1
Abstract Number: 312
Poster Number: 23
Presentation Time: Sunday, April 17, 2016, 1:00 PM – 5:00 PM
Development and Application of a 62-gene Panel for Assessment of Somatic Sequence and Structural Variants in Tumor DNA Derived from non-Hodgkin Lymphoma Patients Treated in a Phase 1 Clinical Trial with the EZH2 Inhibitor Tazemetostat
Speaker: Scott R. Daigle, Epizyme, Inc.
Session Title: Genomic Profiling of Cancers
Abstract Number: 137
Poster Number: 21
Presentation Time: Sunday, April 17, 2016, 1:00 PM – 5:00 PM
The Effect of Tazemetostat on CYP3A-mediated Metabolism of Midazolam in Patients with Solid Tumors
Speaker: Sherri Smith
Session Title: Phase I Clinical Trials in Progress
Abstract Number: CT029
Poster Number: 10
Presentation Time: Monday April 18, 2016 8:00 AM – 12:00 PM
The Effect of Food on the Pharmacokinetics of Tazemetostat in patients with Cancer
Speaker: Benjamin Suttle
Session Title: Phase I Clinical Trials in Progress
Abstract Number: CT031
Poster Number: 12
Presentation Time: Monday April 18, 2016 8:00 AM – 12:00 PM
The Effect of EPZ011989, an Enhancer of Zeste Homolog 2 Inhibitor, in Acute Myeloid Leukemia
Speaker: Sydney Fobare, Hendrix College, Conway, AR
Session Title: Histone Modifications and Chromatin Dynamics
Abstract Number: 4520
Poster Number: 7
Presentation Time: Wednesday, April 20, 8:00 AM – 12:00 PM
About EZH2 in Cancer
EZH2 is a histone methyltransferase (HMT) that is increasingly understood to play a potentially oncogenic role in a number of cancers. These include non-Hodgkin lymphoma, INI1-negative cancers such as malignant rhabdoid tumors and epithelioid sarcomas, certain SMARCA4-negative solid tumors, synovial sarcoma, and a range of other solid tumors.
About Tazemetostat
Epizyme is developing tazemetostat for the treatment of patients with non-Hodgkin lymphoma and for patients with certain genetically defined solid tumors. Tazemetostat is a first-in-class small molecule inhibitor of EZH2 created by Epizyme using its proprietary product platform. In some human cancers, aberrant EZH2 enzyme activity results in dysregulation of genes that control cell proliferation resulting in the rapid and unconstrained growth of tumor cells. Tazemetostat is the WHO International Non- Proprietary Name (INN) for compound EPZ-6438.
Additional information about tazemetostat, including clinical trial information, can be found here.